Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback